Organogenesis (NASDAQ:ORGO) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of Organogenesis (NASDAQ:ORGO) from a buy rating to a sell rating in a report issued on Saturday morning.

ORGO has been the topic of several other research reports. BTIG Research lowered shares of Organogenesis from a “buy” rating to a “neutral” rating in a report on Friday. Weiss Ratings raised shares of Organogenesis from a “sell (d+)” rating to a “hold (c)” rating in a report on Friday, February 27th. One equities research analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $8.50.

Organogenesis Price Performance

Shares of NASDAQ:ORGO opened at $2.37 on Friday. The company’s fifty day moving average price is $2.56 and its 200-day moving average price is $3.89. The firm has a market capitalization of $304.97 million, a price-to-earnings ratio of -12.47 and a beta of 1.31. Organogenesis has a one year low of $2.04 and a one year high of $7.08. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.62 and a quick ratio of 3.32.

Organogenesis (NASDAQ:ORGO) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.08). Organogenesis had a positive return on equity of 9.47% and a negative net margin of 0.84%.The company had revenue of $37.23 million during the quarter, compared to the consensus estimate of $43.26 million.

Insider Activity at Organogenesis

In other Organogenesis news, Director Michael Joseph Driscoll bought 10,000 shares of Organogenesis stock in a transaction that occurred on Monday, March 9th. The shares were bought at an average price of $2.67 per share, with a total value of $26,700.00. Following the acquisition, the director owned 225,707 shares in the company, valued at approximately $602,637.69. This trade represents a 4.64% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 33.00% of the company’s stock.

Institutional Investors Weigh In On Organogenesis

Several institutional investors have recently added to or reduced their stakes in the company. First Light Asset Management LLC boosted its position in Organogenesis by 10.6% during the 3rd quarter. First Light Asset Management LLC now owns 7,497,911 shares of the company’s stock valued at $31,641,000 after buying an additional 720,748 shares during the period. Assenagon Asset Management S.A. boosted its position in Organogenesis by 14.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 5,535,334 shares of the company’s stock valued at $28,673,000 after buying an additional 680,392 shares during the period. Deutsche Bank AG boosted its position in Organogenesis by 0.4% during the 4th quarter. Deutsche Bank AG now owns 3,297,631 shares of the company’s stock valued at $17,082,000 after buying an additional 13,301 shares during the period. Dimensional Fund Advisors LP boosted its position in Organogenesis by 5.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,891,006 shares of the company’s stock valued at $6,851,000 after buying an additional 160,026 shares during the period. Finally, Geode Capital Management LLC boosted its position in Organogenesis by 3.6% during the 4th quarter. Geode Capital Management LLC now owns 1,786,978 shares of the company’s stock valued at $9,259,000 after buying an additional 62,346 shares during the period. Hedge funds and other institutional investors own 49.57% of the company’s stock.

Organogenesis Company Profile

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.